TNF-alpha Neutralization Rate Adalimumab ELISA Assay
The TNF-alpha Neutralization Rate Adalimumab ELISA Assay is For Research Use Only
Sensitivity: Adalimumab: 0.7 µg/mL; TNF alpha: 4ng/ml
Dynamic Range: Adalimumab: 0.7 – 30 µg/mL; TNF alpha in sample without Adalimumab: 4-400ng/ml;TNF alpha in sample with Adalimumab: 4-160ng/ml
Incubation Time: Overnight
Sample Type: Serum
Sample Size: 60 µL
Tumour necrosis factor (TNFα) is a signalling substance of the immune system which can cause, among other things, the formation of inflammatory mediators in cells. In inflammatory diseases such as rheumatoid arthritis, there is overproduction of TNFα, which can be inhibited by using therapeutic antibodies.
Adalimumab is an IgG1 human monoclonal antibody which is used as a TNFα inhibitor. Adalimumab binds specifically to the TNFα protein and neutralises the biological effect of TNFα.
Adalimumab is approved for the treatment of the following diseases: rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis, but is also used “off-label” for other conditions such as sarcoidosis. In therapy using adalimumab, contraindications such as hypersensitivity to adalimumab and also serious infections, sepsis, tuberculosis and cases of opportunistic infections have been noted. Weakening of the body’s defence is produced by the immunosuppressive effect of adalimumab. Excessive neutralisation of TNFα during treatment with adalimumab increases the risk of developing opportunistic infections. In view of this, monitoring the treatment antibody levels and degree of neutralization of TNFα would appear useful during therapy using the TNFα inhibitor adalimumab. In comparison with the tests available on the market, the recoveryELISA TNFα Neutralization Rate/Adalimumab (RTA) Kit can be used to simultaneously determine the free TNFα target antigen, the available therapeutic antibody adalimumab and its ability to neutralise TNFα.